200 related articles for article (PubMed ID: 22579006)
21. Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver.
Miyamoto M; Iwasaki S; Chisaki I; Nakagawa S; Amano N; Hirabayashi H
Xenobiotica; 2017 Dec; 47(12):1052-1063. PubMed ID: 27892765
[TBL] [Abstract][Full Text] [Related]
22. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
24. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
[TBL] [Abstract][Full Text] [Related]
25. Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.
Van den Bergh A; Sinha V; Gilissen R; Straetemans R; Wuyts K; Morrison D; Bijnens L; Mackie C
Clin Pharmacokinet; 2011 Aug; 50(8):505-17. PubMed ID: 21740074
[TBL] [Abstract][Full Text] [Related]
26. Predicting oral clearance in humans: how close can we get with allometry?
Sinha VK; De Buck SS; Fenu LA; Smit JW; Nijsen M; Gilissen RA; Van Peer A; Lavrijsen K; Mackie CE
Clin Pharmacokinet; 2008; 47(1):35-45. PubMed ID: 18076217
[TBL] [Abstract][Full Text] [Related]
27. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
28. Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR.
Morris ME; Yang X; Gandhi YA; Bhansali SG; Benincosa LJ
Biopharm Drug Dispos; 2012 Jan; 33(1):1-14. PubMed ID: 22170504
[TBL] [Abstract][Full Text] [Related]
29. Interspecies prediction of human drug clearance based on scaling data from one or two animal species.
Tang H; Hussain A; Leal M; Mayersohn M; Fluhler E
Drug Metab Dispos; 2007 Oct; 35(10):1886-93. PubMed ID: 17646280
[TBL] [Abstract][Full Text] [Related]
30. Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling.
Naritomi Y; Sanoh S; Ohta S
Biol Pharm Bull; 2019; 42(3):327-336. PubMed ID: 30828063
[TBL] [Abstract][Full Text] [Related]
31. Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution.
Gombar VK; Hall SD
J Chem Inf Model; 2013 Apr; 53(4):948-57. PubMed ID: 23451981
[TBL] [Abstract][Full Text] [Related]
32. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.
Shin BS; Bulitta JB; Balthasar JP; Kim M; Choi Y; Yoo SD
Cancer Chemother Pharmacol; 2011 Aug; 68(2):465-75. PubMed ID: 21069337
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods.
Mahmood I; Yuan R
Biopharm Drug Dispos; 1999 Apr; 20(3):137-44. PubMed ID: 10211866
[TBL] [Abstract][Full Text] [Related]
35. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.
Tabata K; Hamakawa N; Sanoh S; Terashita S; Teramura T
Eur J Drug Metab Pharmacokinet; 2009; 34(2):117-28. PubMed ID: 19645221
[TBL] [Abstract][Full Text] [Related]
36. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
37. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist.
Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM
Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556
[TBL] [Abstract][Full Text] [Related]
38. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
39. An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic.
Shaw JP; Jaw-Tsai S
Xenobiotica; 2011 Jan; 41(1):82-9. PubMed ID: 20946087
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.
Sukbuntherng J; Cropp G; Hannah A; Wagner GS; Shawver LK; Antonian L
J Pharm Pharmacol; 2001 Dec; 53(12):1629-36. PubMed ID: 11804393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
